American States Water Company vs Ginkgo Bioworks Holdings Inc — how do they compare? American States Water Company trades at $87.85 (market cap $3.47B), while Ginkgo Bioworks Holdings Inc trades at $7.25 (market cap $505.73M). The key difference: American States Water Company is far larger — about 6.9× Ginkgo Bioworks Holdings Inc's market cap, and American States Water Company pays a 2.49% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| AWR | DNA | |
|---|---|---|
Market Cap | $3.47B | $505.73M |
Sector | Utilities | Health |
52-Week High | $89.28 | $16.14 |
52-Week Low | $70.10 | $5.48 |
Enterprise Value | $4.37B | $607.68M |
Dividend Yield | 2.49% | — |
Signals from Pluang's Aura AI — not financial advice
AWR trades at $87.95, up 1.59% on the day, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $1.09 versus $0.915 expected, driven by water rate increases and revenue growth. Recent news highlights its 71-year dividend growth streak and an 8.2% dividend hike announced in July 2026. Financials show solid profitability with a 20.52% net income margin and ROE of 13.62%, though valuation ratios like P/E of 23.92 are above sector averages.
Outlook is mixed: strong dividend history and earnings growth support income investors, but elevated valuation and mixed analyst consensus (20% buy, 50% hold, 30% sell) suggest limited near-term upside. Key risks include regulatory dependence on rate approvals and potential overvaluation relative to peers.
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
Trailing returns across standard periods
Latest headlines on both assets
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →